Australia's notifiable diseases status, 1999: Annual report of the National Notifiable Diseases Surveillance System

This article published in Communicable Diseases Intelligence Volume 25, No 4, November 2001 contains the 1999 annual report of National Notifiable Diseases Surveillance System. This annual report is available as 32 HTML documents and is also available in PDF format.

Page last updated: 17 December 2001

A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.


Appendix 1 - Case Definitions



The following table displays the case definitions for vaccine preventable diseases notified to the National Notifiable Diseases Surveillance System in 1999. If you are not able to access these data please e-mail cdi.editor@health.gov.au

Appendix 1f. Case definitions and ICD-10 code for notifiable diseases reported to NNDSS in 1999, vaccine preventable diseases

Disease
Case definition (NHMRC 1994)
ICD-10 code(s)
Diphtheria Isolation of toxigenic Corynebacterium diphtheriae

AND pharyngitis and/or laryngitis (with or without a membrane

OR toxic (cardiac or neurological) symptoms

A36
Haemophilus influenzae type B An invasive clinically compatible illness (meningitis, epiglottitis, cellulitis, septic arthritis, osteomyelitis, pneumonia, pericarditis or septicaemia)

AND either the isolation of Haemophilus influenzae type b (Hib) from blood

OR detection of Hib antigen (in a clinical case)

OR detection of Gram-negative bacteria where the organism fails to grow in a clinical case

A41.3, GO0.0, JO5.1
Measles An illness characterised by all the following features: a generalised maculopapular rash lasting three or more days

AND a fever (at least 38oC if measured)

AND cough or coryza or conjunctivitis or Koplik spots

OR Demonstration of measles specific IgM antibody

OR A four-fold or greater change in measles antibody titre between acute and convalescent-phase sera obtained at least 2 weeks apart, with tests preferably conducted in parallel at the same laboratory

OR Isolation of the measles virus from a clinical specimen

OR A clinically compatible case epidemiologically related to another case

BO5
Mumps Isolation of mumps virus from a clinical specimen

OR significant rise in mumps antibody level by any standard serological assay, except following immunisation

OR a clinically compatible illness (unilateral or bilateral swelling of the parotid or other salivary glands lasting 2 days or more without other apparent cause)

B26
Pertussis Isolation of Bordetella pertussis from a clinical specimen

OR elevated Bordetella pertussis-specific IgA in serum or B. pertussis antigen in a nasopharyngeal specimen using immunofluorescence with a history of clinically compatible illness

A37
Poliomyelitis Acute onset of a flaccid paralysis of one or more limbs with decreased or absent tendon reflexes in the affected limbs without other apparent cause, without sensory or cognitive loss A80
Rubella A generalised maculopapular rash and fever

AND one or more of: arthralgia/arthritis

OR lymphadenopathy

OR conjunctivitis

AND an epidemiological link to a confirmed case

OR demonstration of rubella-specific IgM antibody, except following immunisation

OR a four-fold or greater change in rubella antibody titre between acute and convalescent-phase sera obtained at least 2 weeks apart

BO6
Tetanus A clinically compatible illness without other apparent cause, with or without a history of injury and with or without laboratory evidence of the organism or its toxin A33


This article was published in Communicable Diseases Intelligence Volume 25, No 4, November 2001.

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now